Biotron Ltd
ASX:BIT

Watchlist Manager
Biotron Ltd Logo
Biotron Ltd
ASX:BIT
Watchlist
Price: 0.003 AUD Market Closed
Market Cap: 4m AUD

Operating Margin
Biotron Ltd

-79.2%
Current
-175%
Average
-6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-79.2%
=
Operating Profit
-1.4m
/
Revenue
1.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
Biotron Ltd
ASX:BIT
4m AUD
-79%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
325B USD
30%
US
Amgen Inc
NASDAQ:AMGN
146.5B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
127.6B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.7B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
117.3B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
64.3B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
37.2B USD
-5%

Biotron Ltd
Glance View

Market Cap
4m AUD
Industry
Biotechnology

Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The company is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The firm's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The firm progresses its Hepatitis B virus (HBV) program. The company also designs and develops drugs drugs that target a class of viral proteins known as viroporins.

BIT Intrinsic Value
0.016 AUD
Undervaluation 82%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-79.2%
=
Operating Profit
-1.4m
/
Revenue
1.8m
What is the Operating Margin of Biotron Ltd?

Based on Biotron Ltd's most recent financial statements, the company has Operating Margin of -79.2%.

Back to Top